Moon Shot concentrates on treating, preventing high-risk multiple myeloma
Multiple myeloma is the second most common hematological malignancy in the United States, and it¡¯s increasing in incidence. An estimated 32,110 new cases will be diagnosed in 2019, with nearly 13,000 deaths caused by the disease. Certain patients have what is known as high-risk multiple myeloma (HRMM), meaning they have distinct molecular features that lead to more rapid progression and poorer outcomes.
The High-Risk Multiple Myeloma...
Moon Shot helps corner aggressive-variant prostate cancer
Prostate cancer is the most common cancer diagnosed in American men, and the second leading cause of cancer death in men. While hormone-based...
Immunotherapy drug extends survival for kidney cancer patients
For the first time, a new drug from the field of immuno-oncology has proven to extend survival for patients with advanced kidney cancer, a...
Former four-star admiral tapped as moon shots leader
MD Anderson has appointed former U.S. Public Health Service four-star Admiral Joxel Garcia, M.D. as the inaugural executive director of the cancer prevention and control platform, part of MD Anderson¡¯s Moon Shots Program.
¡°I¡¯m honored to join the No. 1 cancer center in the nation,¡± said Garcia. ¡°It¡¯s truly exciting to join the MD Anderson family and work with world-class leaders, researchers and clinicians.¡±
The Moon Shots...
